Thioacetazone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Thioacetazone
Structural formula of thioacetazone
Space-filling model of thioacetazone
Clinical data
Trade names Conteben
AHFS/Drugs.com International Drug Names
Routes of
administration
Oral
ATC code
Identifiers
Synonyms N-[4-[(Carbamothioylhydrazinylidene) methyl]phenyl]acetamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.002.882
Chemical and physical data
Formula C10H12N4OS
Molar mass 236.29 g·mol−1
3D model (Jmol)
 NYesY (what is this?)  (verify)

Thioacetazone (INN and BAN; also called amithiozone (USAN), thiocetazone, thiacetazone, thiosemicarbazone, or benzothiozane) is a pharmaceutical drug used in the treatment of tuberculosis;[1] it has only weak activity against Mycobacterium tuberculosis and is only useful in preventing resistance to more powerful drugs such as isoniazid and rifampicin. It is never used on its own to treat tuberculosis; it is used in a similar way to ethambutol.

There is no advantage to using thioacetazone if the regimen used already contains ethambutol, but many countries in sub-Saharan Africa still use thioacetazone because it is extremely cheap. Use of thioacetazone is declining because it can cause severe (sometimes fatal) skin reactions in HIV positive patients.[2][3]

Adverse effects[edit]

One of the documented adverse effects of thioacetazone is the excessive accumalation of serum (or blood plasma) in the brain. Another is weakening of the thyroid glands. These were found in a treatment combining conteben with PAS acid p-amino-salicylic acid.[4]

References[edit]

  1. ^ Martindale, The Extra Pharmacopoeia, 30th ed, p. 217
  2. ^ Rieder HL, Arnadottir T, Trebucq A, Enarson DA (2001). "Tuberculosis treatment: dangerous regimens?". Int J Tuberc Lung Dis. 5 (1): 1–3. PMID 11263509. 
  3. ^ Nunn P, Porter J, Winstanley P (1993). "Thiacetazone—avoid like poison or use with care?". Trans R Soc Trop Med Hyg. 87 (5): 578–82. PMID 7505496. doi:10.1016/0035-9203(93)90096-9. 
  4. ^ N. Bergqvist and De O. Mare (12 January 1952). "Hypothyroidism and Cerebral Edema Following Combined Treatment of Tuberculosis with Conteben (TB I 698) and p-Amino-Salicylic Acid". doi:10.1111/j.0954-6820.1952.tb14267.x. 

External links[edit]